Allist Initiates Phase 3 Trial of Furmonertinib for Rare EGFR-Mutant Non-Small Cell Lung Cancer
Confirmatory Trial Targeting Rare EGFR Mutations
Shanghai Allist Pharmaceuticals (688578.SS) is conducting a Phase 3 trial (NCT06956001) of furmonertinib mesylate (Ivesa, a Chinese brand) in 300 patients with treatment-naive, advanced non-small cell lung cancer (NSCLC). The trial focuses on patients with P-loop/Ξ±C-helix compression (PACC) mutations or exon 21 L861Q mutations in the EGFR protein. The study is a randomized, open-label trial comparing furmonertinib 240mg once daily with pemetrexed/cisplatin or carboplatin as first-line treatment. It began on November 19, 2024, with primary completion expected in December 2027 and overall completion in July 2028.
Prior Data Supports 240mg Dose Selection
Furmonertinib is a third-generation tyrosine kinase inhibitor (TKI) designed to irreversibly inhibit mutant epidermal growth factor receptor (EGFR) and penetrate the central nervous system. In a prior Phase 1b trial (FURTHER), the confirmed objective response rate (ORR) in treatment-naive PACC patients, as assessed by an independent review committee, was 68.2% in the 240mg group and 43.5% in the 160mg group. The median progression-free survival (PFS) in the 240mg group was 16.0 months. This dose-related difference led to the selection of 240mg in the Phase 3 trial and aims to demonstrate superiority compared to chemotherapy. The stratification for brain metastasis is intended to assess whether intracranial disease control is a clinically meaningful differentiator.
Competition with Existing Treatments
For major non-canonical EGFR mutations, including L861Q, Gilotrif (afatinib, an EGFR/HER2/HER4 inhibitor) from Boehringer Ingelheim and Tagrisso (osimertinib, a mutant EGFR inhibitor) from AstraZeneca (AZN) are recommended treatments. At the 2026 ASCO meeting, the median PFS in patients with non-canonical mutations was 10.6 months for afatinib and 9.4 months for osimertinib. Rybrevant (amivantamab, an EGFR/MET bispecific antibody) from Johnson & Johnson (JNJ) and the combination of Lazcluze (lazertinib, an EGFR TKI) are also clinical competitors. Therefore, this Phase 3 trial requires demonstrating not only superiority over platinum-based chemotherapy, which has limited efficacy, but also indirect competitiveness against already prescribed EGFR-targeted therapies. The fact that PACC accounts for approximately 12% of all EGFR mutations suggests that structure-based patient selection could expand into a commercially viable niche.
Expanding the Approved Asset's Indications
Ivesa was first approved in China in March 2021 as subsequent therapy for EGFR T790M-positive advanced NSCLC and, on June 28, 2022, its approval was expanded to include first-line treatment for patients with exon 19 deletions or L858R mutations. However, the PACC/L861Q indication is currently in Phase 3 development and has not been approved by the FDA, EMA, or PMDA. The FDA granted Breakthrough Therapy Designation on October 30, 2023, for a separate first-line treatment program for exon 20 insertion mutations, but this does not imply approval of the PACC/L861Q indication. Given that AstraZeneca's Tagrisso generated approximately $6.6 billion in sales in 2024, success in rare mutations could further segment the large EGFR market and extend the lifecycle of Allist's approved product.
If the 300-patient Phase 3 trial is successful, furmonertinib will provide confirmatory evidence that it can directly replace chemotherapy as a first-line treatment for PACC/L861Q mutations, and the primary analysis in December 2027 will be a key value inflection point. Researchers will assess whether the confirmed ORR of 68.2% and median PFS of 16.0 months observed in the prior Phase 1b 240mg group are replicated in the randomized Phase 3 trial, particularly in the brain metastasis-stratified subgroup. The competitive benchmarks are Gilotrif/Tagrisso and the combination of Rybrevant/Lazcluze, and Tagrisso's approximately $6.6 billion in sales in 2024 demonstrates the commercial potential of the EGFR-targeted therapy market. Given that PACC accounts for approximately 12% of EGFR mutations, success would allow Shanghai Allist Pharmaceuticals (688578.SS) to expand its approved asset into the rare mutation niche, while failure would result in a discount to the company's valuation due to the discrepancy between the single-arm Phase 1b data and the confirmatory results.
Source: ClinicalTrials.gov (api_ct)